SCHEMBL4609751

SCHEMBL4609751

Cc1ccc2cc(O)c(C(=O)O)cc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 1/20 0.63
MPL P40238 1/20 0.55
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 1/20 0.53
MCL1 Q07820 1/20 0.51
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
MAOB P27338 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
CYP2A6 P11509 3/20 0.48
CYP1A2 P05177 2/20 0.48
POLB P06746 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24895084 1.00 CSNK2A1 (0.63) CSNK2A1MPLMEN1KMT2AALDH1A1
SCHEMBL1250277 0.86 MCL1 (0.68) CSNK2A1MPLMEN1KMT2AMCL1
SCHEMBL16355668 0.85 CYP2A6 (0.55) CSNK2A1MEN1KMT2AALDH1A1CA9
SCHEMBL5369132 0.82 GRIN2D (0.57) CSNK2A1MEN1KMT2AALDH1A1MCL1
SCHEMBL5353853 0.82 GRIN2D (0.57) CSNK2A1MEN1KMT2AALDH1A1MCL1
SCHEMBL216334 0.81 CA12 (0.61) MEN1KMT2AALDH1A1CA12CA1
SCHEMBL124773 0.81 CA12 (0.61) MEN1KMT2AALDH1A1CA12CA1
SCHEMBL29434908 0.81 CA12 (0.61) MEN1KMT2AALDH1A1CA12CA1
SCHEMBL6881678 0.81 CA12 (0.50) MPLMEN1KMT2ACA12CA1
SCHEMBL18775431 0.81 CA12 (0.50) MPLMEN1KMT2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114730665-B Electrolyte for electrolytic capacitor and electrolytic capacitor 富山药品工业株式会社 2024-12-20 CN disclosed
EP-3421549-B1 COLORING COMPOSITION, INKJET RECORDING INK, INKJET RECORDING METHOD, AND INKJET PRINTER CARTRIDGE FUJIFILM CORP (JP) 2023-08-16 EP disclosed
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 US disclosed
WO-2023287067-A1 ANTIBACTERIAL COMPOUND 주식회사 엘지화학 2023-01-19 WO disclosed
US-11410848-B2 Method of forming pattern, method of manufacturing semiconductor device, and pattern-forming material KIOXIA CORPORATION (JP) 2022-08-09 US disclosed
CN-114730665-A Electrolytic solution for electrolytic capacitor and electrolytic capacitor 富山药品工业株式会社 2022-07-08 CN disclosed
US-20210296116-A1 METHOD OF FORMING PATTERN, METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE, AND PATTERN-FORMING MATERIAL KIOXIA CORPORATION (JP) 2021-09-23 US disclosed
US-20170217999-A1 SURFACE PRIMER COMPOSITIONS AND METHODS OF USE ORMCO CORPORATION 2017-08-03 US disclosed
WO-2017132463-A1 SURFACE PRIMER COMPOSITIONS AND METHODS OF USE ACatechol, Inc. (US) 2017-08-03 WO disclosed
US-9622995-B2 Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) Temple University—Of the Commonwealth System of Higher Education (US) 2017-04-18 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
EP-1556896-B1 ANTI-REFLECTIVE COMPOSITIONS COMPRISING TRIAZINE COMPOUNDS BREWER SCIENCE INC (US) 2008-04-09 EP disclosed
EP-1556896-A4 ANTI-REFLECTIVE COMPOSITIONS COMPRISING TRIAZINE COMPOUNDS BREWER SCIENCE INC (US) 2007-05-09 EP disclosed
US-7038328-B2 Anti-reflective compositions comprising triazine compounds BREWER SCIENCE INC. (US) 2006-05-02 US disclosed
EP-1556896-A2 ANTI-REFLECTIVE COMPOSITIONS COMPRISING TRIAZINE COMPOUNDS Brewer Science, Inc. (US) 2005-07-27 EP disclosed
WO-2004036311-A2 ANTI-REFLECTIVE COMPOSITIONS COMPRISING TRIAZINE COMPOUNDS BREWER SCIENCE, INC. (US) 2004-04-29 WO disclosed
US-20040072420-A1 Anti-reflective compositions comprising triazine compounds BREWER SCIENCE, INC 2004-04-15 US disclosed
US-5990332-A EXCELLENT IN CHARGE CONTROL OR CHARGE-ENHANCING PROPERTY, AND TONER FOR DEVELOPING ELECTROSTATIC IMAGES AND POWDERY PAINT FOR ELECTROSTATIC PAINTING ORIENT CHEMICAL INDUSTRIES, LTD. (JP) 1999-11-23 US disclosed
US-5976749-A TONER FOR DEVELOPING ELECTROSTATIC IMAGES ORIENT CHEMICAL INDUSTRIES, LTD (JP) 1999-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217999-A1 SURFACE PRIMER COMPOSITIONS AND METHODS OF USE SP1, GPER1, GRIN1 CSNK2A1 3350/4885MPL 2902/4885MEN1 4073/4885
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC CSNK2A1 1833/4885MPL 2514/4885MEN1 2531/4885
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand IAPP, IRS1, HBB CSNK2A1 2214/4885MPL 3558/4885MEN1 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.